Literature DB >> 22435784

The use of heparin for preventing miscarriage.

Jerome H Check1.   

Abstract

Recommendations for the use of heparin for preventing miscarriage are recently rapidly changing based on evidenced based prospective studies. At present either heparin or low molecular weight heparin (LMWH) is recommended for the antiphospholipid syndrome (APS). However criteria for diagnosing APS have become much stricter. The exact timing of the heparin is still being evaluated since it is not clear if the main therapeutic effect is in inhibition of thrombosis when the heparin could be started at the time in the first trimester when the platelets become thrombophilic or does its main role in improving implantation in which it would be started shortly before or shortly after ovulation. Possibly heparin is superior to LMWH in improving the implantation process though more studies are needed to corroborate or refute this suggestion. At present inherited thrombophilias are not considered a cause of first trimester miscarriage and thus measuring these factors are not recommended. There is no evidence that heparin has any benefit in preventing miscarriage from unexplained causes. Heparin is effective alone and there does not appear to be any extra benefit from adding aspirin (or even aspirin may negate some of its benefits).
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22435784     DOI: 10.1111/j.1600-0897.2012.01119.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  5 in total

1.  Recurrent Miscarriage: Diagnostic and Therapeutic Procedures. Guideline of the DGGG (S1-Level, AWMF Registry No. 015/050, December 2013).

Authors:  B Toth; W Würfel; M K Bohlmann; G Gillessen-Kaesbach; F Nawroth; N Rogenhofer; C Tempfer; T Wischmann; M von Wolff
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-11       Impact factor: 2.915

Review 2.  Anticoagulation in management of antiphospholipid antibody syndrome in pregnancy.

Authors:  Michael D Lockshin
Journal:  Clin Lab Med       Date:  2013-04-19       Impact factor: 1.935

3.  Prophylactic Effects of Bee Venom Phospholipase A2 in Lipopolysaccharide-Induced Pregnancy Loss.

Authors:  Hyunjung Baek; HyeJin Yang; Jong Hoon Lee; Na-Hoon Kang; Jinwook Lee; Hyunsu Bae; Deok-Sang Hwang
Journal:  Toxins (Basel)       Date:  2019-07-12       Impact factor: 4.546

4.  Aspirin and low-molecular weight heparin combination therapy effectively prevents recurrent miscarriage in hyperhomocysteinemic women.

Authors:  Pratip Chakraborty; Sayani Banerjee; Piyali Saha; Shyam Sundar Nandi; Sunita Sharma; Sourendra K Goswami; Baidyanath Chakravarty; Syed N Kabir
Journal:  PLoS One       Date:  2013-09-05       Impact factor: 3.240

5.  Recurrent Miscarriage: Diagnostic and Therapeutic Procedures. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry Number 015/050).

Authors:  Bettina Toth; Wolfgang Würfel; Michael Bohlmann; Johannes Zschocke; Sabine Rudnik-Schöneborn; Frank Nawroth; Ekkehard Schleußner; Nina Rogenhofer; Tewes Wischmann; Michael von Wolff; Katharina Hancke; Sören von Otte; Ruben Kuon; Katharina Feil; Clemens Tempfer
Journal:  Geburtshilfe Frauenheilkd       Date:  2018-04-27       Impact factor: 2.915

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.